Las Condes 26_01

187 / 256

59
La autora declara no tener conflictos de interés, en relación
a este artículo.
13. Curatolo P, Paloscia C, D’Agati E, Moavero R, Pasini A.The neurobiology of
attention deficit/hyperactivity disorder. EJPN 2009; 13: 299-304
14. Rubia K,Alegria A, Brinson H. Imaging the ADHD brain: disorder-specificity,
medication effects and clinical translation. Expert Rev Neurother 2014; 14:
519-538.
15. Rubia K. “Cool” inferior Frontostriatal Dysfunction in Attention-Deficit/
Hyperactivity Disorder Versus “Hot” Ventromedial Orbitofrontal-Limbic
Dysfunction in Conduct Disorder: A Review. Biol Psychiatry 2011; 69:e69-e87.
16. Feldman H, Reiff M. Attention Deficit -Hyperactivity Disorder in Children
and Adolescents. N Engl J Med 2014; 370: 838-846
17. Subcommittee on Attention -Deficit /Hyperactivity Disorder, Stering
Committeee on Quality Improvement and Management. ADHD: Clinical
Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention
-Deficit/Hiperactivity Disorder in Children and Adolescents. Pediatrics 2011;
128: 1007-1022
18. Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-
5). Washington, DC: American Psychiatric Association, 2013.
19. Mitsis E, McKay K, Schulz K, Newcorn J, Halperin J. Parent-Teacher
Concordance for DSM-IV Attention Deficit/Hyperactivity Disorder in a Clinic-
Referred Sample. J. Acad. Child Adolesc. Psychiatry 2000; 39:308-313.
20. Wolraich M, Wibbelsman C, Brown T et al. Attention-Deficit/Hyperactivity
Disorder Among Adolescents: A review of the Diagnosis, Treatment, and
Clinical Implications. Pediatrics 2005; 115:1734-1746
21. Pliszka S and the AACAP Work Group on Quality Issues. Practice
parameter for assessment and treatment of children and adolescents with
Attention-Deficit/Hyperactivity Disorder. J. Am. Acad. Child Adolesc. Psychiatry,
2007; 46:894-921
22. Dunn D, Kronenberger W. Attention deficit. Handbook of Clinical
Neurology, 2013(111), Pediatric Neurology Part 1, chapter 28.
23. Stefanatos G,Baron I.Attention/Hyperactivity Disorder:A Neuropsychological
Perspective Towards DSM-V. Neuropsychol Rev 2007; 17:5-38
24. Sibley M, Pelham W, Molina B et al. Diagnosing ADHD in Adolescence.
Journal of Consulting and Clinical Psychology 2012; 80:139-150.
25. Tannock R. Rethinking ADHD and LD in DSM -5: Proposed Changes in
Diagnostic Criteria. Journal of Learning Disabilities 2013; 46: 5-25
26. Barkley R, Fisher M, Smallish L, Fletcher K.The persistence of attention deficit
hyperactivity disorder into Young adulthood as a function of reporting source
and definition disorder. Journal of Abnormal Psychology 2002: 111; 279-289
27. Vogel W. An update on attention deficit hyperactivity disorder (ADHD). S.
Afr. Med J. 2014; 104:72-74.
28. Obioha O, Adesman A. Pearls, perils and pitfalls in the assessment and
treatment of attention-deficit/hyperactivity disorder in adolescents. Curr Opin
Pediatr 2014; 26: 119-129
29. Mindell J. A Clinical Guide to Pediatric Sleep: Diagnosis and Management
of sleep problems, 2nd ed. Philadelphia: Lippincott Wuilliams & Wilkins.
30. Millichap G, Yee M. The Diet Factor in Attention -Deficit/Hyperactivity
Disorder. Pediatrics 2012;129:1-8
31. Bloch MH, Qawasmi A. Omega -3Fatty Acid Supplementation for
the Treatment of Children with Attention Deficit/Hyperactivity Disorder
Symptomatology: Systematic Review and Meta-Analysis. Am Acad Child
Adolesc Psychiatry 2011; 50: 991-1000
32. Bisoglio J, Michaels T, Mervis J, Ashinoff B. Cognitive enhancement trough
action video game training: great expectations require greater evidence.
Frontier in Psychology 2014; 5: 136-140
33. Biederman J, Faraone S. Attention-deficit hyperactivity disorder. Lancet
2005; 366:237-248.
34. Newcorn J, Kratchvil C, Allen A et al. Atomoxetine and Osmotically
Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity
Disorder: Acute Comparison and Differential Response. Am J Psychiatry 2008;
165:721-730
35. Daughton J, Kratochvil C. Review of ADHD Pharmacotherapies: Advantages,
Disadvantages, and Clinical Pearls. J Am Child Adolesc Psychiatry 2009: 48: 240-
248.
36. Biederman J, Spencer T, Wilens T. Evidence -based pharmacotherapy
for attention- deficit hyperactivity disorder. International Journal of
Neuropsychopharmacology. 2004; 7:77-91
37. Faraone S, Biderman J, Morley C, Spencer T. Effect of Stimulants on Height
and Weight: A Review of the Literature. Acad: Child Adolesc. Psychiatry.
2008; 47: 994-1009
38. Cortese S, Holtmann M, Banaschewski et al. Practitioner Review: Current
best practice in the management of adverse events during treatment with
ADHD medications in children and adolescents. The J of Child Psychol and
Psychiatry 2013; 54:227-246
39. Wilens T, Faraone S, Biederman J, Gunawardene S. Does Stimulant
Therapy of Attention-Deficit/Hyperactivity Disorder Beget Later. Pediatrics
2003;111;179
40. Van den Ban E, Souverein P, Meijer W et al . Association between ADHD
drug use and injuries among children and adolescents . Eur Child Adolesc
Psychiatry 2014; 23:95-102
41. Childress A, Berry S. Pharmacotherapy of Attention -Deficit Hyperactivity
Disorder in adolescents. Drug 2012; 72:309-325
42. Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of
long term adherence to stimulant treatment in children with ADHD. J Am Acad
Child Adoles Psychiatry 2001; 40: 922-928
43. Shaw M, Hodkings P, Caci H, Young S et al. A systematic review and
analysis of long term outcomes in attention deficit hyperactivity disorder:
effects of treatment and non-treatment. BMC medicine2012; 10:99-125
44. Ilieva I, Farah M. Enhancement stimulants: perceived motivational and
cognitive advantages. Frontiers in Neuroscience 2013; 7: 198-204
[Trastorno por Déficit de Atención e Hiperactividad (TDAH) en adolescentes - Dra. Eliana Rodillo B.]